13D Filing: Celgene Corp /de/ and Alliqua Biomedical Inc. (NASDAQ:ALQA)

SCHEDULE 13D

(1) Includes 7,046,100 shares of Common Stock and 979,094 shares
of Common Stock underlying warrants that are exercisable immediately; provided, however, that the
exercise of the warrants is subject to the Ownership Cap described in Item 6 herein.

(2) The percentage ownership is based on 36,137,486 shares of
Common Stock outstanding as of February 28, 2017, which includes (i) 35,158,392 shares of Common Stock outstanding as reported
by Alliqua BioMedical, Inc. to Celgene Corporation on such date, and (ii) 979,094 shares
of Common Stock underlying warrants held by Celgene Corporation that are exercisable
immediately; provided, however, that the exercise of the warrants is subject to the
Ownership Cap described in Item 6 herein.